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Abstract
Background: Evidence-informed deliberative processes (EDPs) were recently introduced to guide health technology 
assessment (HTA) agencies to improve their processes towards more legitimate decision-making. The EDP framework 
provides guidance that covers the HTA process, ie, contextual factors, installation of an appraisal committee, selecting 
health technologies and criteria, assessment, appraisal, and communication and appeal. The aims of this study were to 
identify the level of use of EDPs by HTA agencies, identify their needs for guidance, and to learn about best practices.
Methods: A questionnaire for an online survey was developed based on the EDP framework, consisting of elements that 
reflect each part of the framework. The survey was sent to members of the International Network of Agencies for Health 
Technology Assessment (INAHTA). Two weeks following the invitation, a reminder was sent. The data collection took 
place between September-December 2018. 
Results: Contact persons from 27 member agencies filled out the survey (response rate: 54%), of which 25 completed all 
questions. We found that contextual factors to support HTA development and the critical elements regarding conducting 
and reporting on HTA are overall in place. Respondents indicated that guidance was needed for specific elements related 
to selecting technologies and criteria, appraisal, and communication and appeal. With regard to best practices, the 
Canadian Agency for Drugs and Technologies and the National Institute for Health and Care Excellence (NICE, UK) 
were most often mentioned. 
Conclusion: This is the first survey among HTA agencies regarding the use of EDPs and provides useful information 
for further developing a practical guide for HTA agencies around the globe. The results could support HTA agencies in 
improving their processes towards more legitimate decision-making, as they could serve as a baseline measurement for 
future monitoring and evaluation.
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Implications for policy makers
• The evidence-informed deliberative processes (EDPs) framework can support the decision-making process of health technology assessment 
(HTA)-agencies but is also relevant for countries that have not (yet) established such an agency. It takes the current  decision-making context as 
the starting point, and offers specific advice depending on the level of HTA development. 
• Using EDPs can contribute to the legitimacy of recommendations and/or decisions, eg, by improving the quality, consistency and transparency 
of the HTA process.
• The results provide an overview of the level of use of EDPs by HTA agencies around the globe. It includes best practices for the different parts 
of the EDP framework, and as such the results are practice-oriented and meant to be inspirational to improve HTA practices. 
Implications for the public
Health technology assessment (HTA) is intended to inform decision-making, including decisions regarding which health technologies (eg, drugs, 
medical devices, surgical procedures, vaccination programs) should be reimbursed or not (anymore). There is a need for structured, explicit and 
transparent approaches with regard to how such decisions are made to facilitate legitimate decision-making. Current HTA methodologies and 
decision-making informed by HTA only partly respond to these requirements. Using evidence-informed deliberative processes (EDPs) can support 
this; by enhancing stakeholder deliberation throughout the HTA process it contributes to the legitimacy of recommendations and/or decisions. This 
manuscript provides insight in (a) how HTA agencies ideally should organise their processes in line with EDPs, which could include the involvement 
of citizens and their views; and (b) to what extent this is currently being implemented by members of the International Network of Agencies for 
Health Technology Assessment (INAHTA). 
Key Messages 
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Background 
Health technology assessment (HTA) is used to inform 
decision-making, such as coverage-decision making, and is 
described as a process that includes governance and structure, 
scoping, assessment, appraisal and implementation and 
monitoring.1 There is broad recognition that current HTA 
processes are ill fitted to take into account the wide range and 
diversity of stakeholder values and lead to insufficient sets of 
information. Ethical issues in particular are left unaddressed, 
thereby compromising the legitimacy of eventual decisions. 
The call for a more integrative perspective on HTA aligns with 
evidence-informed deliberative processes (EDPs) that were 
recently introduced to support HTA agencies in organizing 
legitimate processes.2,3 Although the use of EDPs is relatively 
new, deliberative methods have been developed and used to 
some extent in the field of HTA since the 2000s.4-9 
EDPs draw on this earlier work and provide a structured 
process in which stakeholders participate throughout the 
HTA process to identify criteria for the selection of health 
technologies and assessment, to interpret forthcoming 
evidence, and to deliberate on recommendations and 
decisions.10,11 EDPs are based on rational decision-making 
through evidence-informed evaluation of identified relevant 
values (reflected as criteria used in multi-criteria decision 
analyses [MCDAs]) as well as fair decision-making (as 
reflected in the accountability for reasonableness approach 
– A4R). The underlying premises of the EDP framework 
are: (1) that involvement of relevant stakeholders to identify, 
reflect, and learn about the meaning and importance of 
relevant values and questions, and (2) an evidence-informed 
evaluation of the identified values (criteria), can contribute 
to the legitimacy of recommendations and/or decisions by 
improving the quality, consistency and transparency of the 
HTA process.
Some HTA agencies already have several of these 
components in place (eg, the Canadian Agency for 
Drugs and Technologies in Health [CADTH], Scottish 
Medicines Consortium, National Institute for Health and 
Care Excellence [NICE] in the United Kingdom, and the 
National Committee for Health Technology Incorporation 
[CONITEC] in Brazil).11 Several approaches undertaken by 
these agencies rely on deliberative processes, for example 
regarding identifying topics for HTA and how to appraise 
health technologies. These agencies may serve as inspiration 
for others, especially those who have recently formally set-
up their HTA practice (eg, the Ministry of Public Health in 
Uruguay, and the Centre of Standardization of the Republican 
Centre for Health Development in Kazakhstan), but they can 
also improve regarding certain components.3 
In order to support HTA agencies in the use of EDPs, we 
recently developed a first version of a guide.12 In this practical 
guide, we describe the EDP framework that consists of 5 steps 
and contextual factors for HTA development (Figure).
We defined the core elements of each step on the basis of our 
previous work in this field,3,10 and existing checklists such as 
the checklist for HTA reports from the International Network 
of Agencies for Health Technology Assessment (INAHTA).13 
The way in which these steps can be applied in a specific 
country or region depends on the context, and therefore is 
not meant as a blueprint.
To identify the level of use of EDPs by HTA agencies, and 
to further develop the guide to support HTA agencies, we felt 
it was important to collect views and experiences from HTA 
agencies around the globe. We therefore conducted a survey 
among INAHTA member agencies to identify the current 
level of use of EDPs, identify the need for guidance regarding 
elements of the framework, and to learn about best practices. 
In this article, we present the main findings from the survey.
Methods
A questionnaire for a semi-structured online survey was 
developed based on the EDP framework, consisting of 
elements that reflect each step of the framework and the 
contextual factors for HTA development. We also asked 
respondents to list any element that they felt was missing and 
for best practices regarding each part of the framework. The 
questionnaire is provided as Supplementary file 1.
We contacted the INAHTA secretariat for supporting us 
in contacting their members. INAHTA is a network of 50 
HTA agencies that support health system decision-making in 
31 countries around the globe (2018 figures). The INAHTA 
secretariat provided consent and agreed to send an invitation 
to participate in the survey to their members through email. 
Two weeks following the initial invitation, a reminder was sent 
by the research team, targeting the contact persons as listed 
on the INAHTA website, which is publicly available. A second 
reminder was sent 2 weeks after the first reminder. The data 
collection took place, using the online tool CheckMarket, 
between September-December 2018. 
In the introduction to the survey, we made clear that all 
answers were treated confidential, ie, no attribution would be 
made to specific persons. Two survey respondents explicitly 
wished not to disclose their affiliation. Therefore, we provide 
the results anonymously, presenting the main results and 
highlighting specific areas that were felt to be in need of 
Figure. The Steps of EDPs. Abbreviation: EDPs, evidence-informed deliberative 
processes.
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guidance. We used basic descriptive statistics (frequencies, 
presented as percentage), derived from the CheckMarket tool, 
to summarize the findings.
Results 
Response Rate
Twenty-five completed survey forms were received from 
15 European HTA agencies, 4 HTA agencies were located 
in the Asia-Pacific region (15%), 3 HTA agencies in Latin-
America (11%), 2 came from North-America (7%) and 1 was 
situated in South-Africa (4%). We received incomplete survey 
responses from 5 other HTA agencies, of which we included 
the survey responses from 2 European HTA agencies that 
provided meaningful responses to some of the questions 
(63%). As the number of member agencies was 50 in 2018, the 
overall response rate was 54%. This is comparable with other 
studies that surveyed INAHTA members.14,15 In addition, the 
distribution of HTA agencies providing responses, per region 
can be considered a representative reflection of the INAHTA 
membership. From the 50 member agencies, 64% is located in 
Europe, 14% in the Asia-Pacific region, 10% in Latin-America 
as well as in North-America, and 2% in South-Africa; http://
www.inahta.org. 
Contextual Factors
All agencies were asked about the presence of factors that are 
supportive of HTA development and whether these were in 
need of guidance in their specific context, ie, factors reflecting 
the linkage between HTA practice and policy; the level of 
institutionalization of HTA and the ability to networking 
and capacity building. Overall, the respondents mentioned 
that the contextual factors were present in their contexts, and 
up to 30% of the respondents felt that guidance was needed 
for specific factors (Table 1). There was no clear distinction 
between member agencies with a longer (well-established 
agencies; 93%) or shorter tradition (agencies that are new, in 
the process of being established, and/or are not yet producing 
HTA reports; and a member of INAHTA for less than 2 years) 
of HTA development (7%).
Nineteen respondents (70%) answered the question 
about which HTA practice serves as best practice. Of these 
respondents, 21% mentioned CADTH, followed by NICE 
(16%). 
Step 1 – Installation of an Appraisal Committee/Stakeholder 
Panel
With regard to the existence of an appraisal committee/
stakeholder panel and related guidance it became clear that 
62% of the respondents mentioned to have such a committee 
installed in their country. Two respondents questioned the 
need for one central committee, and mentioned that it could 
be beneficial to have several specialised committees (eg, for 
drugs and medical devices) with overlapping functions and 
responsibilities. A publicly available guideline or document 
that describes the roles and responsibilities of the committee/
panel (remit and scope), and the procedures followed was 
present according to slightly more than half of the respondents 
(54% and 58%, respectively). A document that describes 
the composition, terms, and selection of members, as well 
as the roles and responsibilities of stakeholders involved 
in the process was felt to be less often present (46%). The 
respondents expressed the need for guidance with respect 
to various elements of an appraisal committee/stakeholder 
panel, ranging from 38%–46% for the different elements 
(Table 2). Two respondents also explicitly mentioned that 
training of stakeholders about how to contribute to an 
appraisal committee/panel could be beneficial. 
We also asked the respondents if they were aware of any 
HTA practice that could serve as best practice. Of the 19 
respondents that answered this question (73%), both CADTH 
and NICE were mentioned each by 21%. 
Table 1. Views Regarding the Presence of Contextual Factors and the Need for Guidance (n = 27)








A (formal) mechanism or process to link HTA to policy-making (eg, legislation) 52% 48% 0% 30%
Allocation of public funding to HTA on an annual basis 74% 15% 11% 26%
A policy statement on the willingness to use HTA in policy and/or practice 74% 22% 4% 26%
Institutional 
environment
An independent organizational structure and/or institutional set-up for HTA (HTA 
organization or HTA focal point) 
78% 22% 0% 22%
HTA process guidelines (is a systematic process in place eg, assessment and 
appraisal)
67% 30% 4% 26%
HTA method guidelines (eg, for conducting economic analysis or clinical 
assessment)
67% 33% 0% 22%
Networking and 
capacity
An (inter)national networking strategy for collaboration between HTA 
organization(s) and relevant stakeholders 
52% 33% 15% 30%
Sufficient capacity to carry out HTA 52% 41% 7% 30%
Ability to review international literature (ie, access to databases), including 
expertise in searching the internet
93% 7% 0% 4%
(Domestic) HTA training opportunities (short courses, workshops, master programs 
and PhD training)  
59% 33% 8% 22%
Abbreviation: HTA, health technology assessment.
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Step 2 – Selecting Technologies and Criteria
The elements in relation to selecting technologies and criteria 
(ie, existence of an early warning system/horizon scanning, 
and existence of a scoping procedure) were most often not 
present or present to some extent, according to the majority 
of the respondents. Also, more than half of the respondents 
felt that guidance was needed for almost all specific elements; 
with regard to the methods used for horizon scanning 46% of 
the respondents had the opinion that guidance was needed 
(Table 3).
Fourteen respondents (54%) answered the question 
regarding best practices for horizon scanning. Of these 
respondents, 14% mentioned the UK National Institute 
for Health Research Innovation Observatory, CADTH 
was also mentioned by 14%, as well as the Spanish cross-
regional collaboration between HTA agencies in the field 
of non-pharmaceuticals,16 and EuroScan, a non-for-profit 
network and scientific association of public HTA agencies, 
scientific organizations and individuals for sharing and 
collecting information and development of methods for the 
early identification, appropriate use and awareness of health 
technologies.17 CADTH was specifically mentioned as a best 
practice in relation to scoping by several respondents.
Step 3 - Assessment
The findings show that 2 out of the 3 elements related to 
conducting and reporting assessments are present in most 
of the HTA practices surveyed. The element that was mainly 
present to some extent concerns stakeholder consultation to 
review the plausibility of the evidence reports. However, the 
respondents overall felt that there was less need for guidance 
regarding the elements linked to the assessment phase, ranging 
from 12%–32% for the different elements (Table 4). By those 
who answered the question on best practices (63%), European 
Network for Health Technology Assessment (EUnetHTA) 
(HTA Core Model18 and methodological guidelines) was 
mentioned as a best practice example by 35%, followed by the 
Cochrane Handbook for Systematic Reviews of Interventions 
(12%).19
Step 4 – Appraisal
With regard to the appraisal phase it became clear that all 
the surveyed elements (existence of a formal framework/
approach and a publicly available document/guideline for 
conducting the appraisal) are present in less than half of the 
responding HTA agencies. More than half of the respondents 
mentioned that there was a need for guidance; only with 
regard to the process less than half (44%) of the respondents 
felt that guidance was needed (Table 5). Three respondents 
explicitly mentioned the need to receive guidance on how to 
involve stakeholders in the appraisal process. Sixty percent of 
the respondents answered the question on best practices. Of 
these, 20% mentioned NICE as best practice for undertaking 
appraisal, followed by CADTH (13%).
Step 5 – Communication and Appeal
Almost all respondents (92%) indicated that decisions and the 
underlying reasons are made public or made public to some 
Table 2. Views Regarding the Presence of Elements Related to an Appraisal Committee/Stakeholder Panel, and the Need for Guidance (n = 26)





Existence of a committee for appraisal/HTA decision-making or a 
stakeholder panel
62% 35% 3% 42%
Guidelines/document – 
that is publicly available 
– describing
The composition, terms, and selection of members 46% 35% 19% 38%
The roles and responsibilities of the committee/panel (remit and scope) 58% 27% 15% 38%
The roles and responsibilities of stakeholders involved in the process 46% 31% 23% 46%
The (formal) approach(es) followed by the committee/panel 54% 31% 15% 46%
Abbreviation: HTA, health technology assessment.
Table 3. Views Regarding the Presence of Elements Related to Selecting Technologies and Criteria, and the Need for Guidance (n = 26)





Existence of an early warning system/horizon scanning system 27% 35% 38% 73%
Guidelines/document – 
that is publicly available 
– describing
The process of identification and selection of health technologies (ie, 
procedures, criteria)
35% 50% 15% 58%
The roles and responsibilities of stakeholders involved in the process 23% 31% 46% 58%
The methods used 35% 38% 27% 46%
Existence of a scoping procedure for HTA 35% 35% 30% 54%
Guidelines/document – 
that is publicly available 
– describing
The process of scoping (ie, procedures, criteria) 31% 35% 34% 54%
The roles and responsibilities of stakeholders involved 8% 58% 34% 65%
The methods used 27% 38% 35% 62%
Abbreviation: HTA, health technology assessment.
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extent, and 60% indicated that there is no need for guidance 
in this respect. However, guidelines or documents describing 
the mechanism(s) for appeal, how to propose revisions, 
and to receive a reasoned response, as well as addressing 
monitoring and evaluation of the process were less present. 
Not surprisingly, more than half of the respondents felt that 
there is a need for guidance (52% and 56%, respectively) 
(Table 6). With regard to best practices, NICE was mentioned 
by 14% of the respondents (56%) to this sub-question.
Discussion 
This semi-structured survey intended to collect views and 
experiences from HTA agencies around the globe in order to 
identify the level of use of EDPs by HTA agencies, and to further 
develop the EDP guide to support HTA agencies. The level of 
use of EDPs was measured by asking respondents about the 
extent to which elements of the EDP framework were present 
and whether there was a need for further guidance. We found 
that contextual factors to support HTA development and 
the critical elements regarding conducting and reporting on 
HTA are in place. This is reflecting current HTA practice 
of the respondents, as most INAHTA members are already 
well-established HTA agencies. However, respondents 
indicated that guidance was needed for specific elements 
related to selecting technologies and criteria, appraisal, and 
communication and appeal. Guidance was especially felt in 
terms of the practical organization of meaningful stakeholder 
participation and the methods to include deliberation during 
the appraisal step. As a result, we have updated the practical 
guide12 using these insights. Specifically, we have added 
guidance on stakeholder participation20 as well as guidance 
on how to use MCDA for HTA agencies, based on a recent 
consensus statement among more than 20 experts in the 
field.21
Study Limitations
It is important to highlight the limitations of this study. First, 
the response rate (54%) might suggest that some selection 
bias might be present. However, the survey respondents 
reflect the INAHTA membership (in 2018) in terms of 
geographical representation. As such we feel confident that 
some conclusions can be drawn from this study, even though 
we acknowledge that reports by single persons from an 
INAHTA member agency are not representing the overall 
HTA practice in a particular jurisdiction. In addition, bias 
might be that the responses came from HTA agencies that 
Table 4. Views Regarding the Presence of Elements Related to Conducting and Reporting Assessments, and the Need for Guidance (n = 25)
Element Present Present to Some Extent Not Present
Guidance 
Needed
Publicly available guidelines/ documents on how to undertake the HTA in terms of 
data collection and analysis
72% 24% 4% 12%
Existence of a tool/template for reporting and summarising the (quality of the) 
evidence per relevant aspect as part of HTA (assessment)
76% 20% 4% 24%
Existence of approach for stakeholder consultation to review the plausibility of the 
evidence reports
32% 56% 12% 32%
Abbreviation: HTA, health technology assessment.
Table 5. Views Regarding the Presence of Elements Related to the Appraisal Phase, and the Need for Guidance (n = 25)





Existence of formal framework/approach for appraisal/HTA decision-
making




The process of appraisal (ie, procedures, deliberation) 48% 28% 24% 44%
The roles and responsibilities of stakeholders involved in the process 24% 52% 24% 56%
The methods used 28% 36% 36% 64%
Abbreviation: HTA, health technology assessment.
Table 6. Views Regarding the Presence of Elements Related to Communication and Appeal, and the Need for Guidance (n = 25)





The decisions and the underlying reasons are made public 52% 40% 8% 40%
Guidelines/
documents – that is 
publicly available – 
describing
The mechanism(s) for appeal, how to propose revisions, and to receive a 
reasoned response
24% 40% 36% 52%
The process of monitoring and evaluation of the HTA process and the 
recommendations/guidance or decisions made
20% 36% 44% 56%
Abbreviation: HTA, health technology assessment.
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are already doing quite well, while the survey might not have 
captured responses from less well-established HTA agencies. 
This might have led to an underestimation of the percentage 
of HTA agencies that actually are in need of guidance. We are 
aiming to broadening the survey towards HTA organizations 
from low- and middle-income countries. Second, reporting 
on any set of elements implies that they are equally important, 
but this is not true. Depending on the contextual factors, 
certain steps and/or elements can be more important than 
others. Therefore the findings should be mainly viewed as 
indicative for the level of EDP use by HTA agencies. 
Alignment With Other Study Findings
The findings suggest that contextual factors to support HTA 
development and the critical elements regarding conducting 
and reporting on HTA are currently overall present, mainly in 
countries with well-established HTA practices. Furthermore, 
respondents indicated that specific guidance was needed 
for elements related to selecting technologies and criteria, 
including scoping, appraisal, and communication and appeal. 
These results are in line with the findings of the ISPOR HTA 
Council that recently presented a report on good practices 
in HTA.1 From this report it becomes clear that many good 
practices have been developed in the areas of assessment 
(Step 3), and several with regard to priority setting, scoping 
(Step 2), only a few with regard to structure, governance, 
organizational aspects (Step 1), deliberative processes (Step 
4), and measuring the impact (Step 5). The findings are 
also in line with previous work on priority setting22,23 and 
reported needs of HTA agencies in specific regions. For 
example, in Latin America, the need for transparency in the 
production of HTA, involvement of relevant stakeholders in 
the process, mechanisms to appeal decisions, clear priority-
setting processes, and a clear link between HTA and decision-
making have recently been emphasized.24,25 In addition, HTA 
agencies in Asia recently expressed their need to improve 
transparency and accountability throughout the process. For 
example, it was recommended by the HTAi Asia Policy Forum 
members that a standardized, transparent methodology for 
priority-setting regarding coverage decision-making needs 
to be developed.26 Furthermore, some respondents explicitly 
mentioned particular best practices per step, such as the 
CADTH for scoping, and NICE for having clear procedures in 
place for appeal. Also, Brazil was mentioned as best practice 
for the Latin American region. These findings are in line with 
previous studies in this area.3,27 As such, we feel empowered to 
further optimize the guide on EDPs to support HTA agencies. 
Conclusion
This is the first survey among HTA agencies regarding the 
use of EDPs and provides useful information for further 
developing a practical guide for HTA agencies around the 
globe. Based on the results from the survey, we conclude that 
– as expected – several HTA agencies have already certain 
(elements of) EDPs in place and can serve as inspiration for 
others. The results could also serve as a baseline measurement 
for HTA agencies for future monitoring and evaluation of 
the level of EDP use and to study the effectiveness of EDPs 
in practice. This could support them in improving their 
processes and enhancing legitimate decision-making.
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